Calculating utility: preclinical evidence for cost–benefit analysis by mesolimbic dopamine

Paul E. M. Phillips(University of Washington), Thomas C. Jhou(National Institute on Drug Abuse), Mark E. Walton(University of Oxford)
Psychopharmacology
November 21, 2006
Cited by 238


Related Papers